Medicine Price Control and Article 21: CLAT LR Explainer

📑 On this page

A product reaches the chemist at ₹15. The label on it says ₹250. On 27 October 2026, two Supreme Court judges looked at gaps like this and asked the Centre whether it could show "any justification for this loot".

The bench of Justices Vikram Nath and Sandeep Mehta said the National Pharmaceutical Pricing Authority (NPPA), the body meant to keep medicines affordable, seemed "totally defunct". When the Centre argued for a calibrated approach that does not control the whole pharma market, the bench shot back that patients cannot be weighed against commerce. Then it reserved its order, which means the arguments are over and the judgment will come later.

For a CLAT aspirant, this is a ready-made Legal Reasoning setup: the right to life on one side, freedom of trade and economic policy on the other, and a court working out how far it can push the government. Plus some neat static GK on the NPPA and Article 47.

🎯 In a nutshell

What happened: on 27 October 2026, a Supreme Court bench heard two petitions on medicine pricing and generic prescriptions, attacked the gap between the price to retailer and the MRP, and reserved its order.
The Centre's case: Indian medicine prices are among the lowest in the world, the market is competitive, and a calibrated approach works better than controlling the entire sector.
The Court's pushback: patients have no bargaining power, and their lives cannot be judged through a commercial lens. It asked why a uniform 16% margin cannot apply to all medicines.
Already done: the NPPA has capped trade margins on 137 non-scheduled anti-cancer drugs at 30% of MRP, with revised prices from 9 November 2026. The bench said the government moved only after the Court began asking questions.
Still open: whether the Court will order wider caps, and how far a court can go into economic policy. Nothing on that is decided yet.

📌 What CLAT actually expects

A CLAT passage will hand you the principles: the right to life includes health, trade can be restricted reasonably, and courts do not rewrite economic policy unless a law or right is broken. Your job is to sort the facts into the right box. Is this a regulator failing a duty it already has, or a petitioner asking the court for a policy it merely prefers?

The backstory

Two prices matter in this story. The MRP (maximum retail price) is the most a seller may charge you; it is printed on the pack. The PTR (price to retailer) is what the chemist or hospital pharmacy actually pays. The gap between them is the trade margin, the slice kept by the supply chain.

How India controls medicine prices

The main rulebook is the Drugs (Prices Control) Order, 2013, usually called the DPCO. Drugs are placed under the Essential Commodities Act so that the government can regulate them, and the DPCO is the order that does the regulating. The NPPA implements it.

Medicines on the National List of Essential Medicines (NLEM) go into the DPCO's first schedule and are called scheduled formulations. For these, the NPPA fixes a ceiling price. The formula broadly takes the average price to retailer of the qualifying brands and adds a 16% margin for the retailer. So if that average is ₹100, the ceiling is ₹116.

Everything else is non-scheduled. Makers set the launch price themselves, and the DPCO only limits how much they can raise it each year. One petitioner, Kishan Chand Jain, has argued that around 82% of medicines fall in this category, so most drugs never get an upfront price check.

Where the gap comes from

A ceiling caps the final price, not the markup. The Hindu's editorial of 1 October 2026 gave a clean example: if the ceiling is ₹116 and a hospital negotiates a PTR of ₹50, it can still bill ₹116 and keep ₹66 without breaking any rule.

Hospitals make this worse. Many cancer drugs are not sold over the counter, so the hospital often picks the brand. Companies then compete for the hospital's business, not the patient's, by printing a high MRP and offering a low PTR. Patients who must buy from the in-house pharmacy cannot shop around.

The special power

The DPCO also carries a special power that lets prices be regulated in the public interest, even for drugs outside the schedule. The NPPA has used it before for 106 anti-diabetic and cardiovascular drugs, coronary stents and knee implants. In February 2019, as a trial run, it capped trade margins on 42 non-scheduled anti-cancer drugs, and prices of 526 brands fell by up to 90%, according to the NPPA.

Quick facts: who prices India's medicines

Item	Fact
NPPA	Set up by a Government of India Resolution dated 29 August 1997
Parent department	An attached office of the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers
Its job	Fix and revise drug prices under the DPCO, monitor compliance and availability, advise on pharma policy
DPCO 2013	Issued by the Department of Pharmaceuticals; NLEM medicines are its scheduled formulations
Article 47	Directive Principle: raising nutrition, living standards and public health are among the State's primary duties

→ scroll to see more

What the court said

The Supreme Court is hearing two petitions together. One seeks strict price control under the DPCO and an end to what it calls unethical overpricing and disproportionate profits in the supply chain; the pleas also ask for regulation of launch prices of non-scheduled medicines and price caps on medical devices. The other seeks disciplinary action against doctors who do not prescribe generic medicines.

The build-up

By 1 October 2026: the Court had criticised gaps between PTR and MRP that in some cases reached 1,000%, especially for cancer drugs.
12 October: the Centre said it had decided to cap trade margins on anti-cancer drugs at 30% of MRP, expecting patients to save about ₹2,500 crore a year. The bench called this "hardly anything to be happy about" and pointed to a saline drip sold for ₹270 that cost ₹11.
17 October: the NPPA notified the cap for 137 non-scheduled anti-cancer drugs using that special public-interest power. Prices are expected to fall by up to 70%, the list will be updated periodically, and the revised prices take effect on 9 November 2026.

The hearing on 27 October

Additional Solicitor General Aishwarya Bhati, for the Centre, said the government's policy was that the entire ecosystem should not be controlled. Citing the Centre's affidavit, she said many companies compete in every drug segment, keeping prices among the world's lowest, and stressed the industry's growth.

The bench was unmoved. It asked why there could not be a uniform 16% margin on all medicines, and wanted to know where a 300% or 400% difference goes. It cited a hospital that charged ₹1.30 lakh for an injection available to the distributor at ₹11,000. It said patients have no bargaining power, and that low prices must be judged against India's low per capita income. It also said it wished every medicine were treated as a generic.

Senior advocate Mukul Rohatgi, for hospitals, argued that private hospitals run round-the-clock infrastructure and cannot rely on patients bringing medicines from outside, given the risk of spurious drugs. The bench replied that a commercial hospital charges for everything else, so why should a medicine be billed at 100 or 200 times its price? Hospitals, it said, cannot survive through "dacoity".

You are talking about commerce and economic policy. Don't weigh patients against commerce.

— Supreme Court bench of Justices Vikram Nath and Sandeep Mehta, 27 October 2026 (as reported by PTI)

The principles in play

1. The right to life includes health

The Constitution says no one shall be deprived of life except according to law. The Supreme Court has long read this to include health. In a 1996 case about a man turned away by several government hospitals, it held that the State must protect human life and cannot plead lack of money to escape that duty. If people cannot afford a life-saving drug, the right to life is hollow.

2. Directive Principles guide, but do not command in court

Article 47 tells the State to treat public health as a primary duty. Directive Principles cannot be enforced by a court on their own, but they are fundamental in governing the country, and courts use them to give content to fundamental rights like the right to life.

3. Trade is free, within reasonable limits

Drug makers and hospitals have a fundamental right to carry on business. The State may still impose reasonable restrictions in the interests of the general public. A price ceiling on a necessity is a classic example, and price control is a subject on which both Parliament and the States may make laws.

4. Courts do not pick economic policies

This is the Centre's best card. The Supreme Court has held that the wisdom of an economic policy is ordinarily not for courts to judge, unless the policy breaks a statute or the Constitution. Whether to cap all medicines or only some is a policy choice. A court will not impose a 16% margin simply because it thinks that is wiser.

But there is a narrower path. The DPCO already gives the NPPA the power to fix prices and recover overcharges. If a regulator fails to use powers it already has, and lives are at stake, a court can tell it to do its job. That is very different from the court writing the pricing formula itself. Which path the bench takes is the real question in the reserved order.

What is settled and what is open

Settled: the right to life covers health; trade can be reasonably restricted; the 30% cap on 137 anti-cancer drugs is notified and takes effect on 9 November 2026.
Open: whether the Court will order margin caps for other medicines, rules for hospitals, or launch-price control for non-scheduled drugs.
Open: whether it will direct action on generic prescriptions, and how far it will treat this as enforcing a duty rather than making policy.

The debate

The case for a calibrated approach	The case for tighter control
India's medicine prices are among the world's lowest because of competition among many makers.	Low prices mean little in a country with low per capita income, and patients cannot bargain at a hospital counter.
Full government control of the sector would hurt the market and the industry's growth.	Gaps of 300% to 1,000% between PTR and MRP are not competition; they are margins nobody explains.
Pricing is economic policy, and choosing a cap across all drugs belongs to the government, not judges.	The NPPA already has the powers. Asking it to use them enforces the law rather than replacing policy.
Targeted action, like the cap on 137 cancer drugs, fixes the worst cases while balancing affordability with availability and a working supply chain.	That cap came only after court pressure, and the 2019 trial already showed margins could be squeezed.

→ scroll to see more

There is a middle view too. The Hindu's editorial backed the Court but warned that a flat percentage margin can still reward selling pricier drugs. It suggested a regressive margin, a smaller percentage as the price rises, so sellers gain less by pushing expensive brands. The same editorial noted that the Court had earlier refused to intervene in Siddharth Dalmia's case in 2025.

Principles and terms to know

Principle / term	Plain meaning	How it is applied
Right to health	Part of the right to life: access to medical care and affordable medicine.	The State must take reasonable steps; lack of money is no excuse.
Directive Principles	Goals the State must pursue in making laws, such as better public health.	Not enforceable alone, but used to read fundamental rights.
Reasonable restriction	A limit on a freedom, like trade, made in the public interest.	Valid if connected to its aim and not excessive.
Judicial restraint in economic policy	Courts do not judge whether a policy is wise.	They step in only if a law or right is breached.
Direction to perform a duty	A court ordering a body to use powers it already has.	Allowed; it enforces the law instead of making policy.
MRP and PTR	The printed maximum price, and the price the retailer pays.	The gap between them is the trade margin.
Trade margin cap	A limit on how much the supply chain may add.	Targets the markup itself, as in the 30% cancer-drug cap.
Scheduled vs non-scheduled	On the essential list, or not.	Scheduled drugs get ceiling prices; others are priced by makers.
Reserved order	Hearing over, judgment to come later.	Remarks made in court are not yet law.

→ scroll to see more

ℹ️ Good to know, not to memorise

Constitution: right to life in Article 21; freedom of trade in Article 19(1)(g), restricted under Article 19(6); public health in Article 47; Directive Principles not court-enforceable under Article 37; "Price control" is entry 34 of the Concurrent List. Law: drugs are regulated under section 3 of the Essential Commodities Act, 1955; the special public-interest pricing power is paragraph 19 of the DPCO, 2013. Cases: Paschim Banga Khet Mazdoor Samity v. State of West Bengal (1996) on medical care and Article 21; BALCO Employees' Union v. Union of India (2001) on courts and economic policy.

⚠️ Reasoning traps

1. "The Court has capped all medicine prices." No. The order is reserved; only the NPPA's 30% cap on 137 cancer drugs is in force. 2. "Directive Principles can be enforced like rights." Not on their own; they shape how rights are read. 3. "Any price control violates freedom of trade." No, reasonable restrictions in the public interest are allowed. 4. "Courts can choose a better economic policy." Ordinarily not; they need a breach of law or a right. 5. Ceiling price vs trade margin. A ceiling caps the final price; a margin cap limits the markup between PTR and MRP. 6. Bench remarks are not a ruling. Quote them as observations, not law.

How CLAT could test this

🧩 Worked example

Every person has a right to life, and courts have long read this right to include access to health care. A right that exists only on paper means little to a patient who cannot afford the medicine that keeps her alive. So the State has a duty to take reasonable steps to make essential medicines available and affordable. The Constitution also tells the State to treat the improvement of public health as one of its primary duties. That direction cannot by itself be enforced in a court, but courts use it to understand what the right to life demands. Against this stands the freedom to carry on trade and business. A manufacturer or a hospital is ordinarily free to set its own prices. This freedom is not absolute. The State may place reasonable restrictions on it in the interests of the general public, and fixing a ceiling on the price of a necessity is a familiar example. A restriction is reasonable when it is connected to its purpose and goes no further than needed to achieve it. A measure that singles out one trader for no reason, or shuts down a lawful business when a lighter step would do, fails this test. Courts also accept a limit on their own role. Choosing between economic policies, for instance whether to control prices across a whole industry or only for some products, is the job of the government and the legislature. A court will not strike down an economic policy merely because it believes a different policy would be wiser. It steps in only when the policy, or a failure to act, breaks a law or violates a right. One more distinction matters. Where a law already gives a regulator both the power and the duty to control prices, and the regulator simply fails to use that power, a court may direct the regulator to perform its duty. Ordering a body to do what the law already requires is different from the court designing a pricing policy of its own. Now consider a law. In the country of Sudhana, the Medicine Pricing Act sets up a Pricing Board. The Act empowers the Board to fix ceiling prices for medicines on a notified list of essential medicines, and requires it to recover any amount that a seller charges above the ceiling. Medicines that are not on the list may be priced freely by their makers, though the Act lets the Board report to the government on any medicine whose price it finds unreasonable.

Q1. For three years, pharmacies in Sudhana have sold a listed essential medicine above its ceiling price. Patients have filed dozens of complaints, but the Pricing Board has taken no action. A patient asks the court to intervene. Which is most likely?

AThe court will refuse, because pricing is a matter of economic policy.

BThe court may direct the Board to act and recover the excess, because the Act already gives it that power and duty.

CThe court will itself fix a new, lower ceiling for the medicine.

DThe court will refuse, because the right to life does not cover medicine prices.

▸ Show solution

Answer: B. The passage says that where a law already gives a regulator a power and a duty, and the regulator fails to use it, a court may direct it to perform that duty. The Act requires the Board to recover overcharges, so B fits. A misreads judicial restraint, which concerns choosing between policies, not enforcing existing duties. C goes further than the passage allows, since the court does not design pricing itself. D contradicts the opening principle.

🧩 Worked example

Q2. An association asks the court to order a 10% cap on the margins of all medicines that are not on the essential list, arguing only that such a cap would be a better policy than free pricing. Which is most correct?

AThe court will grant the cap, because health is a primary duty of the State.

BThe court will grant the cap, because free pricing is always an unreasonable restriction.

CThe court is unlikely to grant the cap, because it will not replace an economic policy merely because another seems wiser.

DThe court is unlikely to grant the cap, because price control can never be imposed on unlisted medicines.

▸ Show solution

Answer: C. The petition rests only on the claim that a cap is a better policy. The passage says courts do not strike down economic policies on that ground; they need a breach of law or a right. A relies on a Directive Principle, which cannot be enforced on its own. B confuses the idea: free pricing is not a restriction at all. D overstates the passage, which allows reasonable price restrictions by the State.

🧩 Worked example

Q3. A court upheld a temporary ceiling on the price of oxygen cylinders during an epidemic. In another case, it struck down an order banning one named company, and only that company, from selling cylinders at all, with no reason given. Which principle best explains both results?

ACourts always side with patients against companies.

BA restriction on trade is valid only if it is connected to a public purpose and goes no further than needed.

CDirective Principles override the freedom of trade.

DOnly Parliament, not the government, may restrict trade.

▸ Show solution

Answer: B. The ceiling is tied to a clear public purpose, affordable oxygen in an epidemic, and limits price rather than shutting anyone out. A total ban on one company with no reason has no visible link to any purpose and goes far beyond what is needed. That is the reasonableness test in B. A and C are not principles the passage states, and D invents a rule about who may restrict trade.

🧩 Worked example

Q4. Suppose Sudhana amends the Act so that, in extraordinary circumstances and in the public interest, the Board may cap trade margins on any medicine, listed or not. Citing patients' debts from cancer treatment, the Board caps margins on 50 unlisted cancer drugs at 30% of MRP. A drug maker challenges the cap as a breach of its freedom of trade. Which is most correct?

AThe cap is invalid, because unlisted medicines may be priced freely by their makers.

BThe cap is invalid, because a court cannot allow economic regulation of any kind.

CThe cap is likely valid, because a law now authorises it and it is a reasonable restriction in the public interest.

DThe cap is valid only if every other medicine in the country is also capped.

▸ Show solution

Answer: C. Before the amendment, unlisted medicines were priced freely, so A states the old rule. The amended Act now gives the Board this power, and a margin cap tied to patients' hardship is a restriction connected to a public purpose. B misstates judicial restraint, which leaves room for lawful regulation. D adds a condition the passage never mentions; targeted measures are a legitimate policy choice.

🧩 Worked example

Q5. (Linked GK) Which body, set up in 1997 as an attached office of the Department of Pharmaceuticals, fixes and revises medicine prices under the Drugs (Prices Control) Order?

ACentral Drugs Standard Control Organisation

BNational Pharmaceutical Pricing Authority

CCompetition Commission of India

DNational Medical Commission

▸ Show solution

Answer: B. The NPPA was constituted by a Government of India Resolution of 29 August 1997, under the Department of Pharmaceuticals in the Ministry of Chemicals and Fertilizers. It fixes ceiling prices, monitors compliance and recovers overcharges. The drug regulator CDSCO deals with drug approvals and quality, the CCI with competition, and the NMC with medical education and the profession.

Connect the dots

Constitutional law for CLAT

The right to life, freedom of trade and how courts balance them.

Legal Reasoning

Legal GK and public policy

Regulators, Directive Principles and policy choices.

Legal GK

Economy and business

Price control, markets and regulators in the news.

Current Affairs

Legal GK drill

Quick practice on public policy and legal GK.

Practice

Drill the constitutional principles

Principle-and-facts questions on fundamental rights, like the set above.

Start the constitutional law drill

Sources

Frequently asked questions

What did the Supreme Court say about medicine overpricing on 27 October 2026?

A bench of Justices Vikram Nath and Sandeep Mehta questioned huge gaps between the price to retailer and the MRP, called the NPPA "totally defunct", said patients cannot be weighed against commerce, and reserved its order on two petitions.

Has the Supreme Court capped medicine prices?

No. The order is reserved. The only new cap in force is the NPPA's own: trade margins on 137 non-scheduled anti-cancer drugs are capped at 30% of MRP, with revised prices from 9 November 2026.

What is the NPPA and when was it set up?

The National Pharmaceutical Pricing Authority was set up by a Government of India Resolution on 29 August 1997 as an attached office of the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers. It fixes and revises drug prices under the DPCO and monitors compliance.

What is the difference between a scheduled and a non-scheduled drug?

Scheduled drugs are those on the National List of Essential Medicines; the NPPA fixes their ceiling prices. Non-scheduled drugs are priced by their makers, with only annual increases limited, unless the government uses its special power in the public interest.

Is the right to health a fundamental right in India?

Yes, the Supreme Court reads it into the right to life. Article 47, a Directive Principle, also makes public health a primary duty of the State, though it cannot be enforced in court on its own.

Can a court force the government to cap prices?

Courts do not usually choose economic policy. But if a law already gives a regulator a duty to control prices and it fails to act, a court can direct it to do its job. That line is what CLAT questions test.